Demo mode: simulated data, for showcase onlyDemo mode: simulated data, for showcase onlyDemo mode: simulated data, for showcase only
48%chance
Following Casgevy, more gene-editing therapies are advancing. Resolves YES if the FDA approves a new CRISPR-based gene-editing therapy on or before Dec 31, 2026. Source: FDA.
Great analysis in this thread. Thanks everyone.
This is looking bullish! The momentum is definitely there.
Great analysis in this thread. Thanks everyone.
Adding to my position here. The odds are in our favor.
Looking at the data, this could go either way.
I'm not so sure about this one. The odds seem too high.
Anyone else think this is overvalued right now?
Adding to my position here. The odds are in our favor.
I'm not so sure about this one. The odds seem too high.
The fundamentals support a higher probability here.